A research institute in Abu Dhabi will become the first in the region to locally manufacture and test the safety and effectiveness of an immunotherapy for treating blood cancers, such as myeloma, lymphoma and certain forms of leukaemia.
Abu Dhabi Stem Cells Centre (ADSCC) on Thursday announced that chimeric antigen receptor (CAR) T-cell therapy represents a new, internationally recognised form of immunotherapy.
CAR T-cell therapy harnesses the body’s defence system by reprogramming T-cells, a crucial component in the body’s anti-tumour response, to go on search-and-destroy missions to kill cancer.
These reprogrammed cells become a living drug that mobilises through the body, continually tapping the immune system to attack disease.
